Newsletter - April 2015

Thursday, Apr 9, 2015

The drug Zofran (Ondansetron) was manufactured to help cancer patients to treat nausea that usually follows chemotherapy treatments. The FDA's approval of Zofran was limited to only this use. However, manufacturer GlaxoSmithKline took the liberty of marketing the drug to pregnant women to treat morning sickness. Unfortunately, not only did the FDA not approve the drug for this use, but studies soon found that use of the drug to treat morning sickness was linked to birth defects.

After pleading guilty to federal charges of fraud and illegal promotion, and settling the matter for $3 billion, the manufacturer now faces various others pending lawsuits as a result of the injuries stemming from Zofran's unapproved use.



Neural IT has successfully implemented HIPAA for securing Health records....

ISO 27001 Certification

Neural IT has successfully passed the ISMS re-certification audit and is now ISO 27001:2013 certi...


NSIC-CRISIL has assigned a "SE 2A" rating to Neural IT, indicating a company with High Performanc...



CAALA - "Neural IT is proud to be associated with CAALA (Consumer Attorneys Association of Los An...


CAOC - "Neural IT is proud to be associated with CAOC (Consumer Attorneys of California) as a Ven...


NYSTLA - "Neural IT is proud to be associated with NYSTLA (New York State Trial Lawyers Associati...

News & Events

Valentine's Day Celebration @ Neural IT, 2019!
Neural IT celebrates Valentine's Day each year to convey heartfelt thanks and appreciation to all
Neural IT celebrated its Quarterly Program 'Rewards & Recognition: 2019'
Neural IT celebrated its Quarterly Program 'Rewards & Recognition: 2019,'  a motivational pra
Neural IT New Year Bash 2019
As we welcome year 2019, we also welcome 12 new chapters, 365 new chances.

Latest Tweets